|Articles|September 1, 2001

Depression and Generalized Anxiety Disorder: Managed Care Considerations
Volume 7
Issue 11 Suppl

The Pharmacoeconomics of Venlafaxine in Depression

Author(s)Thomas J. Morrow, MD

Download PDF: The Pharmacoeconomics of Venlafaxine in Depression

Articles in this issue

almost 25 years ago

Article

Participating Faculty

almost 25 years ago

Article

Introduction

almost 25 years ago

Article

Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

almost 25 years ago

Article

Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

almost 25 years ago

Article

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

The Pharmacoeconomics of Venlafaxine in Depression

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Active US Drug Shortages Rise for Third Straight Quarter

Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD